Skip to content

US · CGON · BIOTECHNOLOGY

CG Oncology Inc. (CGON) intrinsic value and stock valuation

$79.47as of 2026-11-21 · Mkt cap 6.39B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CG Oncology Inc. DCF and intrinsic value

InvestorsCraft values CGON with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from CGON’s statements →

CG Oncology Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Dallas, TX 75247 cgoncology.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$4.04M
20212025
Net income
-$-161M
20212025
Free cash flow
-$-132.48M
20212025
Total equity
$752.6M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$4.04M$1.14M$200K$190K$10.4M
Operating income-$-190.77M-$-114.67M-$-55.45M-$-35.25M-$-12.61M
Net income-$-161M-$-88.04M-$-48.61M-$-35.44M-$-12.84M
EPSd-$-2.08M-$-1.41M-$-729.44K-$-531.81K-$-192.68K
Operating cash flow-$-132.35M-$-78.71M-$-45.68M-$-29.8M-$-13.65M
Capital expenditure-$-130K-$-230K$0.00-$-10K-$-100K
Free cash flow-$-132.48M-$-78.95M-$-45.68M-$-29.82M-$-13.75M
Total assets$791.6M$754.8M$199.3M$147.8M$58.7M
Total debt$7.02M$240K$1.03M$15.9M$15.1M
Net debt-$-25.47M-$-256.83M-$-7.24M-$-72.2M-$-38.48M
Total equity$752.6M$733.4M$184.8M$125.2M$40.3M
Cash and short-term investments$742.2M$742M$187.7M$143.5M$53.6M
Income statement
20252024202320222021
Revenue$4.04M$1.14M$200K$190K$10.4M
Cost of revenue$4.65M$82.1M$45.8M$10K$10K
Gross profit-$-610K-$-80.96M-$-45.55M$180K$10.4M
Research and development expenses$116.6M$82.1M$45.8M$29M$18.3M
Selling, general and administrative expenses$73.5M$33.7M$9.9M$6.39M$4.63M
Other expenses$0.00-$-82.1M-$-45.75M$0.00$0.00
Operating expenses$190.2M$33.7M$9.9M$35.4M$23M
Cost and expenses$194.8M$115.8M$55.7M$35.4M$23M
Interest income$29.9M$26.6M$6.9M$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$450K
Depreciation and amortization$1.45M$30K$20K$10K$10K
Ebitda-$-159.55M-$-88.01M-$-48.59M-$-35.43M-$-12.38M
Operating income-$-190.77M-$-114.67M-$-55.45M-$-35.25M-$-12.61M
Total other income/expenses, net$29.8M$26.6M$6.84M-$-200K-$-230K
Income before tax-$-161M-$-88.04M-$-48.61M-$-35.44M-$-12.84M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-161M-$-88.04M-$-48.61M-$-35.44M-$-12.84M
Weighted average shares outstanding$77.3M$62.5M$66.6M$66.6M$66.6M
Weighted average diluted shares outstanding$77.3M$62.5M$66.6M$66.6M$66.6M
Balance sheet
20252024202320222021
Cash and short-term investments$742.2M$742M$187.7M$143.5M$53.6M
Net receivables$690K$780K$90K$300K$0.00
Inventory$1.56M$0.00$0.00$0.00$0.00
Total current assets$759.5M$754.2M$194.1M$147.2M$58.4M
Property, plant and equipment, net$19.6M$490K$490K$510K$200K
Goodwill and intangible assets$10.9M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$32.1M$590K$5.18M$540K$280K
Total assets$791.6M$754.8M$199.3M$147.8M$58.7M
Accounts payable$5.71M$6.52M$3.24M$980K$1M
Short-term debt$920K$190K$790K$9.15M$3.02M
Deferred revenue$290K$0.00$0.00$0.00$0.00
Total current liabilities$30.8M$21.4M$14.3M$15.4M$5.97M
Long-term debt$6.11M$50K$240K$6.79M$12.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$8.15M$50K$260K$7.14M$12.5M
Capital lease obligations$4.02M$240K$460K$450K$120K
Total liabilities$39M$21.4M$14.5M$22.6M$18.4M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-378.98M-$-217.98M-$-129.94M-$-81.33M-$-45.89M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$752.6M$733.4M$184.8M$125.2M$40.3M
Total investments$709.7M$484.9M$179.4M$55.3M$0.00
Total debt$7.02M$240K$1.03M$15.9M$15.1M
Net debt-$-25.47M-$-256.83M-$-7.24M-$-72.2M-$-38.48M
Cash flow statement
20252024202320222021
Net income-$-161M-$-88.04M-$-48.61M-$-35.44M-$-12.84M
Depreciation and amortization$1.45M$30K$20K$10K$10K
Stock-based compensation$26.7M$11.4M$1.53M$680K$1.11M
Change in working capital$2.28M$2.91M$3.44M$4.44M-$-1.97M
Accounts receivable-$-320K-$-690K$0.00$0.00$0.00
Inventory-$-440K$0.00$0.00$0.00$0.00
Accounts payable-$-1.64M$3.27M$2.01M-$-20K$580K
Net cash provided by operating activities-$-132.35M-$-78.71M-$-45.68M-$-29.8M-$-13.65M
Investments in property, plant and equipment-$-130K-$-230K$0.00-$-10K-$-100K
Acquisitions, net-$-21.97M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-245.82M-$-300.76M-$-121.19M-$-55.35M-$-100K
Common stock issued$153.6M$629.5M$2.08M$170K$240K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$153.6M$628.3M$87M$119.7M$15.5M
Net change in cash-$-224.58M$248.8M-$-79.88M$34.5M$1.7M
Cash at end of period$32.5M$257.1M$8.27M$88.1M$53.6M
Operating cash flow-$-132.35M-$-78.71M-$-45.68M-$-29.8M-$-13.65M
Capital expenditure-$-130K-$-230K$0.00-$-10K-$-100K
Free cash flow-$-132.48M-$-78.95M-$-45.68M-$-29.82M-$-13.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CG Oncology Inc.

        CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

        CEO
        Arthur Kuan
        Employees
        142
        Beta
        0.22

        Explore

        Frequently asked questions

        What is the intrinsic value of CG Oncology Inc. (CGON)?

        CG Oncology Inc. (CGON) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CGON undervalued?

        CGON trades at a price of $79.47 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.